(PDF) Stereotactic Ablative Radiotherapy Outcomes for

Stereotactic Ablative Radiotherapy Outcomes for Metastatic Adrenal Gland Tumors in Lung Cancer Based on Histology Subtype and Molecular Profile

International Journal of Radiation Oncology Biology Physics - Netherlands

doi 10.1016/j.ijrobp.2019.06.1316

Full Text

Abstract

Available in full text

Categories

Cancer Research

Nuclear Medicine

Date

September 1, 2019

Authors

Publisher

Elsevier BV

Related search

Imaging Follow-Up After Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors

Journal of Radiation Oncology

Nuclear Medicine

English

Are We Ready for Histology-Driven Stereotactic Ablative Radiotherapy?

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.16-15 Toxicities and Survival After Stereotactic Ablative Radiotherapy (SABR) for Centrally Located Lung Tumors

Journal of Thoracic Oncology

Respiratory Medicine

English

Stereotactic Ablative Radiotherapy for Ultra-Central Lung Tumors: Prioritize Target Coverage or Organs at Risk?

Radiation Oncology

Nuclear Medicine

English

Establishing a Histology-Specific Biologically Effective Dose Threshold for Lung Stereotactic Ablative Radiotherapy (SABR): Is ≥100 Gy10 Enough?

International Journal of Radiation Oncology Biology Physics

Cancer Research

Nuclear Medicine

English

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.16-22 Meta-Analysis of Stereotactic Ablative Radiotherapy Versus Surgery for Early Stage Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Partial Stereotactic Ablative Boost Radiotherapy in Bulky Non-Small Cell Lung Cancer: A Retrospective Study

OncoTargets and Therapy

English

Primary Lung Sarcoma Treated With Stereotactic Ablative Radiotherapy: A Case Report

OncoTargets and Therapy

English